Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 200 Bay Street, Suite 2800 TORONTO ON M5J 2J1 |
Tel: | N/A |
Website: | https://satellos.com |
IR: | See website |
Key People | ||
Andrew J. Rae President, Chief Executive Officer, Director | Elizabeth Williams Chief Financial Officer | Warren Whitehead Head of Corporate Strategy |
Business Overview |
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1. |
Financial Overview |
For the fiscal year ended 31 December 2023, Satellos Bioscience Inc revenues was not reported. Net loss increased 40% to C$15.9M. Higher net loss reflects Professional fees increase of 53% to C$2.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.32 to -C$0.18. |
Employees: | 12 as of Dec 31, 2023 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $13.41M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$15.46M as of Dec 31, 2023 |
Net annual income (TTM): | -$15.89M as of Dec 31, 2023 |
Free cash flow (TTM): | -$32.04M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 112,791,658 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |